NCT06046495View on ClinicalTrials.gov

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

February 9, 2028

Study Completion Date

February 9, 2028

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

PLB1004

PLB1004 will be orally self-administered by the patient as a mono-therapy.

Trial Locations (7)

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

40202

RECRUITING

Research Site, Louisville

68130

RECRUITING

Nebraska Cancer Specialists, Omaha

98122

RECRUITING

Swedish Health Sciences, Seattle

98195

RECRUITING

Research Site, Seattle

100021

RECRUITING

Research Site, New York

95817-1514

RECRUITING

University of California-Davis, Sacramento

All Listed Sponsors
lead

Avistone Biotechnology Co., Ltd.

INDUSTRY